“During the third quarter, our team continued to advance our portfolio while winding down activities surrounding the BEACON-IPF trial,” said Bernard Coulie, President and Chief Executive Officer of Pliant. “Looking ahead, we continue to evaluate a range of opportunities to create shareholder value.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRX:
- Pliant Therapeutics Announces CBO Hans Hull’s Resignation
- Pliant Therapeutics Settles Loan with Oxford Finance
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Align downgraded, NetEase upgraded: Wall Street’s top analyst calls
- Pliant Therapeutics downgraded to Underweight from Neutral at JPMorgan